Advancing clinical biochemistry: addressing gaps and driving future innovations.

Modern healthcare depends fundamentally on clinical biochemistry for disease diagnosis and therapeutic guidance. The discipline encounters operational constraints, including sampling inefficiencies, precision limitations, and expansion difficulties. Recent advancements in established technologies, such as mass spectrometry and the development of high-throughput screening and point-of-care technologies, are revolutionizing the industry. Modern biosensor technology and wearable monitors facilitate continuous health tracking, Artificial Intelligence (AI)/machine learning (ML) applications enhance analytical capabilities, generating predictive insights for individualized treatment protocols. However, concerns regarding algorithmic bias, data privacy, lack of transparency in decision-making ("black box" models), and over-reliance on automated systems pose significant challenges that must be addressed for responsible AI integration. However, significant limitations remain-substantial implementation expenses, system incompatibility issues, and information security vulnerabilities intersect with ethical considerations regarding algorithmic fairness and protected health information. Addressing these challenges demands coordinated efforts between clinicians, scientists, and technical specialists. This review discusses current challenges in clinical biochemistry, explicitly addressing the limitations of reference intervals and barriers to implementing innovative biomarkers in medical settings. The discussion evaluates how advanced technologies and multidisciplinary collaboration can overcome these constraints while identifying research priorities to enhance diagnostic precision and accessibility for better healthcare delivery.